AMGEN INC/ US0311621009 /
2024-05-03 5:32:17 PM | Chg. +34.35 | Volume | Bid5:32:17 PM | Ask5:32:17 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
292.25EUR | +13.32% | 338 Turnover: 98,892.65 |
-Bid Size: - | -Ask Size: - | 155 bill.EUR | - | - |
GlobeNewswire
05-02
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Canc...
GlobeNewswire
05-01
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Su...
GlobeNewswire
05-01
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
04-30
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
04-24
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
04-15
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire
04-15
Shah Capital nominates two highly qualified independent director candidates for Novavax
GlobeNewswire
04-08
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...
GlobeNewswire
04-08
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...